# iQure Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iqure-pharma

- Industry: Biotechnology
- Headquarters: Princeton, US
- Website: www.iqurepharma.com
- Total disclosed funding: $1.5M
- Latest round: Series A (Oct 4, 2023)
- Investors on record: 2

## About

Based in New Jersey, US, and founded in 2019, iQure Pharma Inc., operates as a biotechnology company that researches and provides therapeutic medicine for neuropathic pain. In October 2023, iQure Pharma Inc. raised USD 1.5 million in venture funding co-led by investors OKG Ventures and Ventura BioMEd Investors. As of 2022, the company is led by its CEO, Pawel Zolnierczyk.

The company develops therapies for neuropathic pain by working with academic partners, industry, and patient organizations. The company’s project pipeline includes iQ-007, and iQ-008, which are based on pain-relevant molecular chronic pain and neuropathic pain models.

The company plans to use the October 2023 funding to accelerate the development of iQ-007, a therapeutic candidate to treat epilepsy and other neurodegenerative conditions.

## Funding rounds

- Series A, Oct 4, 2023, $1.5M — Ventura BioMed Investors, OKG Ventures

## Investors

- Ventura BioMed Investors (https://capitalatlas.ai/funds/ventura-biomed-investors) — Series A
- OKG Ventures (https://capitalatlas.ai/funds/okg-ventures) — Series A